Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

A highly facile and specific assay for cancer-causing isocitrate dehydrogenase mutant using 13C4-labeled α-ketoglutarate and heteronuclear NMR.

Wen H, Yun T, Xu WJ, Choi SH, Kim H, Park CK, Lee SH, Park SW, Lee SK, Park S.

Anal Chem. 2013 Dec 17;85(24):11987-92. doi: 10.1021/ac402947a. Epub 2013 Nov 22.

PMID:
24266712
2.

Registered report: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Fiehn O, Showalter MR, Schaner-Tooley CE; Reproducibility Project: Cancer Biology; Reproducibility Project Cancer Biology.

Elife. 2016 Feb 26;5. pii: e12626. doi: 10.7554/eLife.12626.

3.

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.

Wise DR, Ward PS, Shay JE, Cross JR, Gruber JJ, Sachdeva UM, Platt JM, DeMatteo RG, Simon MC, Thompson CB.

Proc Natl Acad Sci U S A. 2011 Dec 6;108(49):19611-6. doi: 10.1073/pnas.1117773108. Epub 2011 Nov 21.

4.

The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.

Chen J, Yang J, Cao P.

Mini Rev Med Chem. 2016;16(16):1344-1358. Review.

PMID:
27292784
5.

Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.

Balss J, Pusch S, Beck AC, Herold-Mende C, Krämer A, Thiede C, Buckel W, Langhans CD, Okun JG, von Deimling A.

Acta Neuropathol. 2012 Dec;124(6):883-91. doi: 10.1007/s00401-012-1060-y. Epub 2012 Nov 2.

PMID:
23117877
6.
7.
8.

Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.

Cairns RA, Mak TW.

Cancer Discov. 2013 Jul;3(7):730-41. doi: 10.1158/2159-8290.CD-13-0083. Epub 2013 Jun 24. Review.

9.

Formation of enzyme bound carbon dioxide in the reductive carboxylation of alpha-ketoglutarate by isocitrate dehydrogenase.

Ramakrishna M, Krishnaswamy PR.

Biochem Biophys Res Commun. 1966 Nov 22;25(4):378-82. No abstract available.

PMID:
4381615
12.

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.

Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y.

Cell Rep. 2015 Dec 22;13(11):2353-61. doi: 10.1016/j.celrep.2015.11.029. Epub 2015 Dec 10.

13.
14.

D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2.

Lin AP, Abbas S, Kim SW, Ortega M, Bouamar H, Escobedo Y, Varadarajan P, Qin Y, Sudderth J, Schulz E, Deutsch A, Mohan S, Ulz P, Neumeister P, Rakheja D, Gao X, Hinck A, Weintraub ST, DeBerardinis RJ, Sill H, Dahia PL, Aguiar RC.

Nat Commun. 2015 Jul 16;6:7768. doi: 10.1038/ncomms8768.

15.

Conditions for (13)C NMR detection of 2-hydroxyglutarate in tissue extracts from isocitrate dehydrogenase-mutated gliomas.

Pichumani K, Mashimo T, Baek HM, Ratnakar J, Mickey B, DeBerardinis RJ, Maher EA, Bachoo RM, Malloy CR, Kovacs Z.

Anal Biochem. 2015 Jul 15;481:4-6. doi: 10.1016/j.ab.2015.04.017. Epub 2015 Apr 20.

16.

α -Ketoglutarate accumulation is not dependent on isocitrate dehydrogenase activity during tellurite detoxification in Escherichia coli.

Reinoso CA, Appanna VD, Vásquez CC.

Biomed Res Int. 2013;2013:784190. doi: 10.1155/2013/784190. Epub 2013 Nov 25.

17.

Registered report: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Evans B, Griner E; Reproducibility Project: Cancer Biology.

Elife. 2015 Jul 31;4:e07420. doi: 10.7554/eLife.07420.

18.

Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.

Zhu J, Zuo J, Xu Q, Wang X, Wang Z, Zhou D.

Med Hypotheses. 2011 Apr;76(4):602-3. doi: 10.1016/j.mehy.2011.01.011. Epub 2011 Feb 1.

PMID:
21284999
19.

Metabolic alteration in tumorigenesis.

Yang H, Xiong Y, Guan K.

Sci China Life Sci. 2013 Dec;56(12):1067-75. doi: 10.1007/s11427-013-4549-2. Epub 2013 Oct 10. Review.

PMID:
24114443
20.

The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases.

Chowdhury R, Yeoh KK, Tian YM, Hillringhaus L, Bagg EA, Rose NR, Leung IK, Li XS, Woon EC, Yang M, McDonough MA, King ON, Clifton IJ, Klose RJ, Claridge TD, Ratcliffe PJ, Schofield CJ, Kawamura A.

EMBO Rep. 2011 May;12(5):463-9. doi: 10.1038/embor.2011.43. Epub 2011 Apr 1.

Supplemental Content

Support Center